| 1.375 -0.015 (-1.08%) | 03-20 13:33 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.16 |
1-year : | 2.52 |
| Resists | First : | 1.85 |
Second : | 2.16 |
| Pivot price | 1.63 |
|||
| Supports | First : | 1.36 |
Second : | 1.13 |
| MAs | MA(5) : | 1.49 |
MA(20) : | 1.61 |
| MA(100) : | 1.82 |
MA(250) : | 2.52 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 4 |
D(3) : | 12.8 |
| RSI | RSI(14): 37.6 |
|||
| 52-week | High : | 7.96 | Low : | 1.3 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LUNG ] has closed above bottom band by 13.2%. Bollinger Bands are 5.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.51 - 1.52 | 1.52 - 1.53 |
| Low: | 1.35 - 1.36 | 1.36 - 1.37 |
| Close: | 1.37 - 1.39 | 1.39 - 1.41 |
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Sun, 15 Mar 2026
LUNG SEC Filings - Pulmonx Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Fri, 13 Mar 2026
LUNG Stock Price, Quote & Chart | PULMONX CORP (NASDAQ:LUNG) - ChartMill
Fri, 13 Mar 2026
Pulmonx Corporation (NASDAQ:LUNG) Given Average Rating of "Hold" by Brokerages - MarketBeat
Tue, 10 Mar 2026
Pulmonx Corporation (LUNG) Releases Q4 2025 Earnings: Revenue Down, Diluted Loss Per Share Widens - Quiver Quantitative
Fri, 06 Mar 2026
Pulmonx Corporation (NASDAQ:LUNG) Q4 2025 earnings call transcript - MSN
Wed, 04 Mar 2026
Lung device maker Pulmonx trims losses, guides 2026 sales to $90–92M - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 41 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 10.7 (%) |
| Held by Institutions | 82.1 (%) |
| Shares Short | 3,280 (K) |
| Shares Short P.Month | 2,630 (K) |
| EPS | -1.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.3 |
| Profit Margin | -59.7 % |
| Operating Margin | -43.9 % |
| Return on Assets (ttm) | -23 % |
| Return on Equity (ttm) | -77.2 % |
| Qtrly Rev. Growth | -5 % |
| Gross Profit (p.s.) | 1.62 |
| Sales Per Share | 2.19 |
| EBITDA (p.s.) | -1.28 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.98 |
| PEG Ratio | 0 |
| Price to Book value | 1.04 |
| Price to Sales | 0.62 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|